INTRODUCTION: Cerebrospinal fluid (CSF) biomarkers can identify individuals with Alzheimer's disease (AD) pathology (eg, amyloid plaques, neurofibrillary tangles), but defined analyte cut-points using high-throughput automated assays are necessary for general clinical use. METHODS: CSF amyloid β42 peptide (Aβ42), t-tau, and t-tau/Aβ42 were quantified by the Lumipulse platform in two test cohorts (A/B: Eisai BAN2401-201/MISSION AD E2609-301/302, n = 138; C: Knight Alzheimer's Disease Research Center (ADRC), n = 198), and receiver operating characteristic (ROC) curve analyses defined cut-points corresponding best to amyloid determinations using positron emission tomography (PET) imaging. The best-performing cut-point was then validated as a predictor of amyloid status in an independent cohort (D: MISSION AD E2609-301/302, n = 240). RESULTS: Virtually identical t-tau/Aβ42 cut-points (∼0.54) performed best in both test cohorts and with similar accuracy (areas under ROC curve [AUCs] [A/B: 0.95; C: 0.94]). The cut-point yielded an overall percent agreement with amyloid PET of 85.0% in validation cohort D. DISCUSSION: Lumipulse CSF biomarker measures with validated cut-points have clinical utility in identifying AD pathology.
INTRODUCTION: Cerebrospinal fluid (CSF) biomarkers can identify individuals with Alzheimer's disease (AD) pathology (eg, amyloid plaques, neurofibrillary tangles), but defined analyte cut-points using high-throughput automated assays are necessary for general clinical use. METHODS: CSF amyloid β42 peptide (Aβ42), t-tau, and t-tau/Aβ42 were quantified by the Lumipulse platform in two test cohorts (A/B: Eisai BAN2401-201/MISSION AD E2609-301/302, n = 138; C: Knight Alzheimer's Disease Research Center (ADRC), n = 198), and receiver operating characteristic (ROC) curve analyses defined cut-points corresponding best to amyloid determinations using positron emission tomography (PET) imaging. The best-performing cut-point was then validated as a predictor of amyloid status in an independent cohort (D: MISSION AD E2609-301/302, n = 240). RESULTS: Virtually identical t-tau/Aβ42 cut-points (∼0.54) performed best in both test cohorts and with similar accuracy (areas under ROC curve [AUCs] [A/B: 0.95; C: 0.94]). The cut-point yielded an overall percent agreement with amyloid PET of 85.0% in validation cohort D. DISCUSSION: Lumipulse CSF biomarker measures with validated cut-points have clinical utility in identifying AD pathology.
Authors: Anne M Fagan; Mark A Mintun; Robert H Mach; Sang-Yoon Lee; Carmen S Dence; Aarti R Shah; Gina N LaRossa; Michael L Spinner; William E Klunk; Chester A Mathis; Steven T DeKosky; John C Morris; David M Holtzman Journal: Ann Neurol Date: 2006-03 Impact factor: 10.422
Authors: Oskar Hansson; Alvydas Mikulskis; Anne M Fagan; Charlotte Teunissen; Henrik Zetterberg; Hugo Vanderstichele; Jose Luis Molinuevo; Leslie M Shaw; Manu Vandijck; Marcel M Verbeek; Mary Savage; Niklas Mattsson; Piotr Lewczuk; Richard Batrla; Sandra Rutz; Robert A Dean; Kaj Blennow Journal: Alzheimers Dement Date: 2018-06-23 Impact factor: 21.566
Authors: Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski Journal: Lancet Neurol Date: 2013-02 Impact factor: 44.182
Authors: James D Doecke; Alan Rembach; Victor L Villemagne; Shiji Varghese; Stephanie Rainey-Smith; Shannon Sarros; Lisbeth A Evered; Christopher J Fowler; Kelly K Pertile; Rebecca L Rumble; Brett Trounson; Kevin Taddei; Simon M Laws; S Lance Macaulay; Ashley I Bush; Kathryn A Ellis; Ralph Martins; David Ames; Brendan Silbert; Hugo Vanderstichele; Colin L Masters; David G Darby; Qiao-Xin Li; Steven Collins Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Yi Su; Tyler M Blazey; Abraham Z Snyder; Marcus E Raichle; Daniel S Marcus; Beau M Ances; Randall J Bateman; Nigel J Cairns; Patricia Aldea; Lisa Cash; Jon J Christensen; Karl Friedrichsen; Russ C Hornbeck; Angela M Farrar; Christopher J Owen; Richard Mayeux; Adam M Brickman; William Klunk; Julie C Price; Paul M Thompson; Bernadino Ghetti; Andrew J Saykin; Reisa A Sperling; Keith A Johnson; Peter R Schofield; Virginia Buckles; John C Morris; Tammie L S Benzinger Journal: Neuroimage Date: 2014-12-05 Impact factor: 6.556
Authors: Qiao-Xin Li; Victor L Villemagne; James D Doecke; Alan Rembach; Shannon Sarros; Shiji Varghese; Amelia McGlade; Katrina M Laughton; Kelly K Pertile; Christopher J Fowler; Rebecca L Rumble; Brett O Trounson; Kevin Taddei; Stephanie R Rainey-Smith; Simon M Laws; Joanne S Robertson; Lisbeth A Evered; Brendan Silbert; Kathryn A Ellis; Christopher C Rowe; S Lance Macaulay; David Darby; Ralph N Martins; David Ames; Colin L Masters; Steven Collins Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Reisa A Sperling; Dorene M Rentz; Keith A Johnson; Jason Karlawish; Michael Donohue; David P Salmon; Paul Aisen Journal: Sci Transl Med Date: 2014-03-19 Impact factor: 17.956
Authors: Emily C Edmonds; Denis S Smirnov; Kelsey R Thomas; Lisa V Graves; Katherine J Bangen; Lisa Delano-Wood; Douglas R Galasko; David P Salmon; Mark W Bondi Journal: Neurology Date: 2021-08-10 Impact factor: 11.800
Authors: Philip Scheltens; Bart De Strooper; Miia Kivipelto; Henne Holstege; Gael Chételat; Charlotte E Teunissen; Jeffrey Cummings; Wiesje M van der Flier Journal: Lancet Date: 2021-03-02 Impact factor: 79.321
Authors: Eline A J Willemse; Betty M Tijms; Bart N M van Berckel; Nathalie Le Bastard; Wiesje M van der Flier; Philip Scheltens; Charlotte E Teunissen Journal: Alzheimers Dement (Amst) Date: 2021-05-01
Authors: Ashvini Keshavan; Henrietta Wellington; Zhongbo Chen; Ayesha Khatun; Miles Chapman; Melanie Hart; David M Cash; William Coath; Thomas D Parker; Sarah M Buchanan; Sarah E Keuss; Matthew J Harris; Heidi Murray-Smith; Amanda Heslegrave; Nick C Fox; Henrik Zetterberg; Jonathan M Schott Journal: Alzheimers Dement (Amst) Date: 2020-09-13
Authors: Katherine J Bangen; Denis S Smirnov; Lisa Delano-Wood; Christina E Wierenga; Mark W Bondi; David P Salmon; Douglas Galasko Journal: Alzheimers Res Ther Date: 2021-07-01 Impact factor: 6.982